Semaglutide Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as NOVO. It is marketed under 3 brand names, including OZEMPIC, RYBELSUS, WEGOVY. Available in 15 different strengths, such as 2MG/1.5ML (1.34MG/ML), 4MG/3ML (1.34MG/ML), 14MG and others, and administered through 2 routes including SOLUTION;SUBCUTANEOUS, TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"3833","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"4f111386adcd4d388b40","publication_number":"US8114833B2","cleaned_patent_number":"8114833","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-08-13","publication_date":"2012-02-14","legal_status":"Granted"} US8114833B2 Formulation 14 Feb, 2012 Granted 13 Aug, 2025
{"application_id":"79668","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"62a3e8627e684e558dba","publication_number":"US8684969B2","cleaned_patent_number":"8684969","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-10-20","publication_date":"2014-04-01","legal_status":"Granted"} US8684969B2 Formulation 01 Apr, 2014 Granted 20 Oct, 2025
{"application_id":"79662","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"9cedbdd4333f40ac8ca1","publication_number":"US10357616B2","cleaned_patent_number":"10357616","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-01-20","publication_date":"2019-07-23","legal_status":"Patented case"} US10357616B2 Formulation 23 Jul, 2019 Patented case 20 Jan, 2026
{"application_id":"79704","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"5a374ba385074edbbcd8","publication_number":"US10376652B2","cleaned_patent_number":"10376652","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-01-20","publication_date":"2019-08-13","legal_status":"Granted"} US10376652B2 Formulation 13 Aug, 2019 Granted 20 Jan, 2026
{"application_id":"79691","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"5a374ba385074edbbcd8","publication_number":"US9108002B2","cleaned_patent_number":"9108002","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-01-20","publication_date":"2015-08-18","legal_status":"Granted"} US9108002B2 Formulation 18 Aug, 2015 Granted 20 Jan, 2026
{"application_id":"79649","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"9cedbdd4333f40ac8ca1","publication_number":"US9861757B2","cleaned_patent_number":"9861757","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-01-20","publication_date":"2018-01-09","legal_status":"Patented case"} US9861757B2 Formulation 09 Jan, 2018 Patented case 20 Jan, 2026
{"application_id":"79703","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"5a374ba385074edbbcd8","publication_number":"US9616180B2","cleaned_patent_number":"9616180","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-01-20","publication_date":"2017-04-11","legal_status":"Granted"} US9616180B2 Formulation 11 Apr, 2017 Granted 20 Jan, 2026
{"application_id":"79624","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"271c1e414a9147f39f9c","publication_number":"US8536122B2","cleaned_patent_number":"8536122","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-03-20","publication_date":"2013-09-17","legal_status":"Patented case"} US8536122B2 Molecular Formulation 17 Sep, 2013 Patented case 20 Mar, 2026
{"application_id":"79751","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"4ba1897ea3eb4d6fbc0b","publication_number":"US8920383B2","cleaned_patent_number":"8920383","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-07-17","publication_date":"2014-12-30","legal_status":"Granted"} US8920383B2 Formulation 30 Dec, 2014 Granted 17 Jul, 2026
{"application_id":"79643","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"881b4bdbb9ab4aa6beab","publication_number":"US11097063B2","cleaned_patent_number":"11097063","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-07-17","publication_date":"2021-08-24","legal_status":"Patented case"} US11097063B2 Formulation 24 Aug, 2021 Patented case 17 Jul, 2026
{"application_id":"79630","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"881b4bdbb9ab4aa6beab","publication_number":"US10220155B2","cleaned_patent_number":"10220155","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-07-17","publication_date":"2019-03-05","legal_status":"Granted"} US10220155B2 Formulation 05 Mar, 2019 Granted 17 Jul, 2026
{"application_id":"79760","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"4ba1897ea3eb4d6fbc0b","publication_number":"US9775953B2","cleaned_patent_number":"9775953","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-07-17","publication_date":"2017-10-03","legal_status":"Granted"} US9775953B2 Formulation 03 Oct, 2017 Granted 17 Jul, 2026
{"application_id":"79779","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"97e2c7b58dfe44829ebd","publication_number":"USRE46363E","cleaned_patent_number":"RE46363","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-08-03","publication_date":"2017-04-11","legal_status":"Expired"} USRE46363E1 Formulation 11 Apr, 2017 Expired 03 Aug, 2026
{"application_id":"79683","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"62a3e8627e684e558dba","publication_number":"US9687611B2","cleaned_patent_number":"9687611","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-02-27","publication_date":"2017-06-27","legal_status":"Patented case"} US9687611B2 Formulation 27 Jun, 2017 Patented case 27 Feb, 2027
{"application_id":"79661","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"9cedbdd4333f40ac8ca1","publication_number":"US9457154B2","cleaned_patent_number":"9457154","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-09-29","publication_date":"2016-10-04","legal_status":"Granted"} US9457154B2 Formulation 04 Oct, 2016 Granted 29 Sep, 2027
{"application_id":"79591","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"271c1e414a9147f39f9c","publication_number":"US8129343B2","cleaned_patent_number":"8129343","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-12-05","publication_date":"2012-03-06","legal_status":"Patented case"} US8129343B2 Molecular Formulation 06 Mar, 2012 Patented case 05 Dec, 2031
{"application_id":"128965","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"f57d759307394de5a77d","publication_number":"US10086047B2","cleaned_patent_number":"10086047","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-12-16","publication_date":"2018-10-02","legal_status":"Patented case"} US10086047B2 Formulation 02 Oct, 2018 Patented case 16 Dec, 2031
{"application_id":"5975","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"f57d759307394de5a77d","publication_number":"US10960052B2","cleaned_patent_number":"10960052","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-12-16","publication_date":"2021-03-30","legal_status":"Patented case"} US10960052B2 Formulation 30 Mar, 2021 Patented case 16 Dec, 2031
{"application_id":"5962","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"f57d759307394de5a77d","publication_number":"US11382957B2","cleaned_patent_number":"11382957","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-12-16","publication_date":"2022-07-12","legal_status":"Patented case"} US11382957B2 Formulation 12 Jul, 2022 Patented case 16 Dec, 2031
{"application_id":"5977","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"f57d759307394de5a77d","publication_number":"US9278123B2","cleaned_patent_number":"9278123","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-12-16","publication_date":"2016-03-08","legal_status":"Patented case"} US9278123B2 Formulation 08 Mar, 2016 Patented case 16 Dec, 2031
{"application_id":"79765","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"1bc4f3ad275844b9a2ed","publication_number":"US9132239B2","cleaned_patent_number":"9132239","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-02-01","publication_date":"2015-09-15","legal_status":"Granted"} US9132239B2 Formulation 15 Sep, 2015 Granted 01 Feb, 2032
{"application_id":"98709","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"9f1f7a8758a14e3d9421","publication_number":"US10933120B2","cleaned_patent_number":"10933120","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-15","publication_date":"2021-03-02","legal_status":"Patented case"} US10933120B2 Formulation 02 Mar, 2021 Patented case 15 Mar, 2033
{"application_id":"116753","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"9f1f7a8758a14e3d9421","publication_number":"US11759502B2","cleaned_patent_number":"11759502","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-15","publication_date":"2023-09-19","legal_status":"Patented case"} US11759502B2 Formulation 19 Sep, 2023 Patented case 15 Mar, 2033
{"application_id":"128969","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"9f1f7a8758a14e3d9421","publication_number":"US11759501B2","cleaned_patent_number":"11759501","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-15","publication_date":"2023-09-19","legal_status":"Patented case"} US11759501B2 Formulation 19 Sep, 2023 Patented case 15 Mar, 2033
{"application_id":"116754","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"9f1f7a8758a14e3d9421","publication_number":"US11759503B2","cleaned_patent_number":"11759503","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-15","publication_date":"2023-09-19","legal_status":"Patented case"} US11759503B2 Formulation 19 Sep, 2023 Patented case 15 Mar, 2033
{"application_id":"39076","ingredient":"SEMAGLUTIDE","trade_name":"WEGOVY","family_id":"81f889ee83f04499813c","publication_number":"US9764003B2","cleaned_patent_number":"9764003","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-06-21","publication_date":"2017-09-19","legal_status":"Patented case"} US9764003B2 19 Sep, 2017 Patented case 21 Jun, 2033
{"application_id":"39077","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"81f889ee83f04499813c","publication_number":"US10335462B2","cleaned_patent_number":"10335462","drug_product_flag":"-, Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-06-21","publication_date":"2019-07-02","legal_status":"Patented case"} US10335462B2 02 Jul, 2019 Patented case 21 Jun, 2033
{"application_id":"98703","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"88b195de230d433388fc","publication_number":"US12239739B2","cleaned_patent_number":"12239739","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-05-02","publication_date":"2025-03-04","legal_status":"Patented case"} US12239739B2 Molecular Formulation 04 Mar, 2025 Patented case 02 May, 2034
{"application_id":"98675","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"88b195de230d433388fc","publication_number":"US10278923B2","cleaned_patent_number":"10278923","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-05-02","publication_date":"2019-05-07","legal_status":"Granted"} US10278923B2 07 May, 2019 Granted 02 May, 2034
{"application_id":"80336","ingredient":"SEMAGLUTIDE","trade_name":"WEGOVY","family_id":"76efe21a995c44129618","publication_number":"US11752198B2","cleaned_patent_number":"11752198","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-24","publication_date":"2023-09-12","legal_status":"Patented case"} US11752198B2 Formulation 12 Sep, 2023 Patented case 24 Aug, 2038
{"application_id":"123894","ingredient":"SEMAGLUTIDE","trade_name":"WEGOVY","family_id":"76efe21a995c44129618","publication_number":"US12214017B2","cleaned_patent_number":"12214017","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-24","publication_date":"2025-02-04","legal_status":"Granted"} US12214017B2 Formulation 04 Feb, 2025 Granted 24 Aug, 2038
{"application_id":"80317","ingredient":"SEMAGLUTIDE","trade_name":"WEGOVY","family_id":"76efe21a995c44129618","publication_number":"US10888605B2","cleaned_patent_number":"10888605","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-24","publication_date":"2021-01-12","legal_status":"Patented case"} US10888605B2 Formulation 12 Jan, 2021 Patented case 24 Aug, 2038
{"application_id":"39098","ingredient":"SEMAGLUTIDE","trade_name":"WEGOVY","family_id":"91edb6520a33447b8d52","publication_number":"US12029779B2","cleaned_patent_number":"12029779","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-10-10","publication_date":"2024-07-09","legal_status":"Patented case"} US12029779B2 09 Jul, 2024 Patented case 10 Oct, 2038
{"application_id":"141164","ingredient":"SEMAGLUTIDE","trade_name":"OZEMPIC","family_id":"91edb6520a33447b8d52","publication_number":"US12295988B2","cleaned_patent_number":"12295988","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-10-10","publication_date":"2025-05-13","legal_status":"Patented case"} US12295988B2 13 May, 2025 Patented case 10 Oct, 2038
{"application_id":"137311","ingredient":"SEMAGLUTIDE","trade_name":"RYBELSUS","family_id":"7ed0b046287a4d10b128","publication_number":"US11833248B2","cleaned_patent_number":"11833248","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-02-01","publication_date":"2023-12-05","legal_status":"Granted"} US11833248B2 Formulation 05 Dec, 2023 Granted 01 Feb, 2039
{"application_id":"80339","ingredient":"SEMAGLUTIDE","trade_name":"WEGOVY","family_id":"85c427b385b643058d59","publication_number":"US11318191B2","cleaned_patent_number":"11318191","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-02-17","publication_date":"2022-05-03","legal_status":"Patented case"} US11318191B2 Formulation 03 May, 2022 Patented case 17 Feb, 2041

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Semaglutide

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.